Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 9/20 | 0.37 |
| ▸ | PTK6 | Q13882 | 2/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | PLAT | P00750 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL796252 | 1.00 | BTK (0.38) | BTKF10PTK6GPR119FPR2 | |
| Hydrochloric Acid SCHEMBL797766 | 0.99 | BTK (0.37) | BTKF10PTK6GPR119FPR2 | |
| SCHEMBL2597108 | 0.97 | PTK6 (0.37) | BTKF10PTK6GPR119FPR2 | |
| SCHEMBL15022863 | 0.97 | PTK6 (0.37) | BTKF10PTK6GPR119FPR2 | |
| SCHEMBL789215 | 0.94 | FPR2 (0.41) | PTK6GPR119FPR2PLATCYP3A4 | |
| SCHEMBL2597001 | 0.94 | FPR2 (0.41) | PTK6GPR119FPR2PLATCYP3A4 | |
| SCHEMBL796253 | 0.88 | F10 (0.35) | BTKF10GPR119SLC6A9CYP3A4 | |
| SCHEMBL796254 | 0.88 | F10 (0.35) | BTKF10GPR119SLC6A9CYP3A4 | |
| Hydrochloric Acid SCHEMBL790095 | 0.88 | GPR119 (0.35) | BTKF10GPR119SLC6A9CYP3A4 | |
| SCHEMBL797270 | 0.86 | FPR2 (0.35) | BTKF10FPR2PLATCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
| EP-2571864-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | Array Biopharma, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2011146335-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | BTK 3330/4885F10 3693/4885PTK6 2698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.